Last reviewed · How we verify
Chlorhexidine Gluconate 2% Wipe
At a glance
| Generic name | Chlorhexidine Gluconate 2% Wipe |
|---|---|
| Sponsor | University of Chicago |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) (PHASE2)
- Effect of Bed Bathing Methods on VRE Colonization in ICU Patients (NA)
- Bacterial Decolonization Within Dyads (NA)
- Animal-Assisted Visitation Program Chlorhexidine Trial (PHASE4)
- A Pilot Study to Evaluate Skin Swabbing With Chlorhexidine to Prevent Skin And Soft Tissue Infections Among People Who Inject Drugs (PHASE4)
- Skin Preparation for Elective Foot and Ankle Surgery (PHASE4)
- Optimizing Infection Prophylaxis Prior to Shoulder Surgery (NA)
- Preventing Diabetic Foot Ulcers Through Cleaner Feet (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chlorhexidine Gluconate 2% Wipe CI brief — competitive landscape report
- Chlorhexidine Gluconate 2% Wipe updates RSS · CI watch RSS
- University of Chicago portfolio CI